
Opinion|Videos|September 4, 2024
Evaluating Cretostimogene: BOND-003 and PIVOT-006 Trial Results
Panelists discuss whether the trial results support investigating cretostimogene with other checkpoint inhibitors and provide insights into notable ongoing trials exploring cretostimogene for intermediate- or high-risk NMIBC, such as BOND-003 and PIVOT-006.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Do you think the results of this trial support the investigation of cretostimogene in combination with other checkpoint inhibitors?
- Can you briefly discuss other notable trials that are investigating cretostimogene for intermediate- or high-risk NMIBC?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA updates in urology: December 2025
2
TRT myths, metabolic risk, and the role of the urologist
3
How sex influences the bladder cancer tumor microenvironment
4
John Michael DiBianco, MD, highlights trial of stent omission after ureteroscopy
5



















